Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Multicenter, Dose Escalation and Confirmation Study of PRT2527 in Participants With Advanced Solid Tumors

NCT05159518 is registered in ClinicalTrials.gov with Prelude Therapeutics as lead sponsor.

NCT NCT05159518
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05159518 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Multicenter, Dose Escalation and Confirmation Study of PRT2527 in Participants With Advanced Solid Tumors
Lead sponsor
Prelude Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
February 14, 2022
Completion date
December 6, 2023
Enrollment
30 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

castrate resistant prostate cancer, hormone receptor positive her2 negative breast cancer, non-small cell lung cancer, sarcoma, solid tumors with known myc amplification